NovaBridge Biosciences (NBP) Debt to Equity (2018 - 2023)
NovaBridge Biosciences (NBP) has 4 years of Debt to Equity data on record, last reported at $0.02 in Q4 2023.
- On a quarterly basis, Debt to Equity rose 167.77% to $0.02 in Q4 2023 year-over-year; TTM through Dec 2023 was $0.02, a 167.77% increase, with the full-year FY2023 number at $0.02, up 164.56% from a year prior.
- Debt to Equity reached $0.02 in Q4 2023 per NBP's latest filing, up from $0.01 in the prior quarter.
- Over the last five years, Debt to Equity for NBP hit a ceiling of $0.02 in Q4 2023 and a floor of -$0.02 in Q4 2019.
- A 3-year average of $0.0 and a median of $0.01 in 2022 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: soared 70.66% in 2019, then skyrocketed 167.77% in 2023.
- Tracing NBP's Debt to Equity over 3 years: stood at -$0.02 in 2019, then skyrocketed by 126.51% to $0.01 in 2022, then surged by 167.77% to $0.02 in 2023.
- Business Quant data shows Debt to Equity for NBP at $0.02 in Q4 2023, $0.01 in Q2 2023, and $0.01 in Q4 2022.